Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Nasal spray could replace needles for sickle cell pain emergencies

NCT ID NCT04076748

First seen Jun 12, 2026 · Last updated Jun 23, 2026 · Updated 3 times

Summary

This study tested a nasal spray containing a strong painkiller (sufentanil) for adults with sickle cell disease experiencing a painful crisis. The goal was to see if it could provide faster relief than the standard gas mixture (EMONO) before giving morphine through an IV. The trial was stopped early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CH de Cayenne

    Cayenne, 97306, French Guiana

  • CHU Pointe à Pitre

    Les Abymes, 97159, Guadeloupe

  • Gonesse Hospital

    Gonesse, 95500, France

  • Hopital Pellegrin

    Bordeaux, 33000, France

  • Hôpital Charles Nicolle

    Rouen, 76031, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

  • Hôpital Louis Mourier

    Colombes, 92700, France

  • Hôpital Rangueil

    Toulouse, 31059, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sufentanil (a strong painkiller given as a nasal spray)

What this could lead to

If it worked, this could offer a faster, needle-free way to ease severe sickle cell pain in the emergency room.

What could go wrong

The trial was terminated early, so results are limited. It is unclear if the nasal spray works better than the standard gas treatment, and strong painkillers carry risks like drowsiness or breathing problems.

Conditions

The condition(s) this trial relates to.

agnosia sickle cell disease Vaso-Occlusive Crises

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.